Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06795412Phase 1Recruiting

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Role: lead

NCT05720117Phase 1Recruiting

A Study of PYX-201 in Advanced Solid Tumors

Role: lead

NCT03389802Phase 1Active Not Recruiting

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

Role: collaborator

NCT05718557Phase 1Active Not Recruiting

Study of PYX-106 in Solid Tumors

Role: lead

All 4 trials loaded